The first HPV vaccine reached the public in June 2006, when the U.S. Food and Drug Administration approved Gardasil, a quadrivalent vaccine targeting four strains of human papillomavirus. That makes the vaccine roughly nineteen years old as of 2025. But the scientific groundwork stretches back further, into the late 1980s, and the vaccine itself has gone through multiple generations since that initial approval. Nearly two decades of real-world data have revealed both how well the vaccine works and how much the landscape of HPV prevention has changed since those early days.
The Research That Made It Possible
The HPV vaccine’s origin story begins with Harald zur Hausen, a German virologist who identified human papillomavirus as the primary cause of cervical cancer. That discovery, which eventually earned him a Nobel Prize in 2008, set off a race to develop a preventive vaccine. Research in the late 1980s and early 1990s showed that when scientists expressed the major capsid protein of HPV in laboratory systems, it spontaneously assembled into virus-like particles, or VLPs. These particles looked and behaved like the real virus on the outside but carried no viral DNA inside, making them harmless yet highly effective at training the immune system to recognize HPV.1ACS Publications (Europe PMC). The HPV Vaccine Story That VLP platform became the backbone of every HPV vaccine that followed.
From VLP discovery to licensure took about fifteen years. Large-scale clinical trials in the early 2000s established that the vaccines were safe and that they prevented persistent HPV infections and precancerous cervical lesions with striking efficacy. By the time Gardasil cleared the FDA in June 2006, the evidence was strong enough that public health agencies worldwide moved quickly to incorporate it into routine immunization schedules.
Three Generations of Vaccine
Since 2006, three distinct HPV vaccines have come to market. The original Gardasil was a quadrivalent vaccine covering HPV types 6, 11, 16, and 18. Types 16 and 18 are responsible for the majority of HPV-related cancers, while types 6 and 11 cause most genital warts. A second vaccine, Cervarix, followed and targeted only types 16 and 18 using a different adjuvant system.2PubMed Central. HPV Vaccines – An Overview
The biggest leap came in 2014 with the approval of Gardasil 9, a nonavalent vaccine. It covers the same four types as the original plus five additional high-risk strains: HPV 31, 33, 45, 52, and 58. Those five extra types account for about 20 percent of cervical cancers that the earlier vaccines missed.3PubMed Central. The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC Altogether, the nine-valent vaccine covers the high-risk HPV types responsible for roughly 90 percent of cervical cancers.4JNCI Monographs. Deintensification of cervical cancer screening in the era of high human papillomavirus–vaccination coverage Today, Gardasil 9 is the only HPV vaccine available in the United States. Both the original Gardasil and Cervarix have been phased out of the U.S. market, though Cervarix remains in use in some other countries.
If you were vaccinated with an earlier version, the shift to Gardasil 9 raised practical questions. Guidelines suggest the nine-valent vaccine can be used to complete an incomplete course started with one of the older vaccines, and it may also be added to a previously completed schedule to broaden protection against the additional strains.5PubMed. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines
What Nearly Two Decades of Data Show
One of the advantages of the HPV vaccine’s age is the wealth of follow-up data that has accumulated. A ten-year follow-up study of women who received the HPV 16/18 vaccine found continued protection against the most serious precancerous cervical changes. Among unvaccinated women, 75 cases of the highest-grade cervical lesions and four cases of invasive cervical cancer were identified. Among vaccinated women, only four high-grade lesions were found. The overall vaccine efficacy against these serious lesions was about 66 percent when counting all participants regardless of whether they followed the full protocol.6BMJ Open. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials
Population-level data tell an even more dramatic story. In England, women who were offered vaccination routinely at age 12 to 13 saw cervical cancer rates drop by about 84 percent and high-grade precancerous lesion rates fall by about 94 percent compared to women who were never offered the vaccine. By mid-2020, the English vaccination program had prevented an estimated 687 cervical cancers and over 23,000 high-grade precancerous lesions.7PubMed. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study A Swedish study found that women vaccinated at age 16 or younger had an 86 percent lower rate of cervical cancer compared to unvaccinated women.8PubMed Central. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer Across countries with high vaccine uptake and routine vaccination programs, systematic reviews consistently show substantial decreases in HPV infection, precancerous lesions, and cervical cancer.9PubMed Central. Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review
Age at vaccination matters a great deal. The biggest benefits consistently show up in people vaccinated before any exposure to HPV, which is why public health campaigns focus on preteens. The further you get from that window, the smaller the incremental benefit, because more people have already encountered the virus through sexual contact.
Herd Protection and Genital Warts
Some of the earliest visible signs of the vaccine’s impact came not from cancer data, which takes years to appear, but from genital warts. Australia, which rolled out a school-based vaccination program with high uptake, reported a 92.6 percent reduction in genital warts among women under 21 in areas where about 70 percent of the population received three doses.10PubMed Central. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review Denmark saw similarly steep declines in both women and men during the post-vaccination period.11PubMed. Human papillomavirus-associated cancers, precancers, and genital warts in Denmark, 2000-2022
What was particularly revealing was the effect on unvaccinated people. In Scotland, researchers tracking HPV prevalence between 2009 and 2013 found that infection rates with HPV 16 and 18 dropped even among unvaccinated women, falling from a steady rate of about 30 percent to roughly 21 percent by 2013.12Emerging Infectious Diseases. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 Australia reported a rapid decline in genital warts diagnoses among young women within just two years of launching its program, with some benefit showing up in heterosexual men as well.13PubMed. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women This herd protection effect was one of the stronger early arguments for achieving high coverage rates, since vaccinating enough of the population slows transmission to everyone.
Beyond Cervical Cancer
HPV does not only cause cervical cancer. The same virus drives cancers of the anus, throat, penis, vagina, and vulva. The vaccine’s reach into those areas has become clearer over time. A randomized trial in men who have sex with men found that the quadrivalent vaccine reduced anal precancerous lesions related to the targeted HPV types by about 75 percent among those who followed the full protocol, and cut persistent anal HPV infections by roughly 95 percent in that group.14PubMed. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia A meta-analysis of randomized trials confirmed that HPV vaccination effectively blocks infection not just at the cervix but also at the anus and in the oral cavity.15Public Health. The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis
These findings are relevant because HPV-related throat and anal cancers have been rising in many countries, even as cervical cancer rates decline. Throat cancers linked to HPV now represent a growing share of head and neck cancers, particularly in men. The vaccine’s ability to prevent oral HPV infection suggests a future payoff in reduced throat cancer rates, though we are still years away from seeing that in population data because these cancers develop slowly.
From Girls Only to Gender-Neutral Programs
When the HPV vaccine launched, it was approved and recommended only for girls and young women. The rationale was straightforward: cervical cancer was the primary target, and vaccinating girls before sexual debut offered the most direct protection. But the logic for including boys was always there. Males carry and transmit the virus, they develop their own HPV-related cancers, and vaccinating only half the population leaves transmission chains intact.
The FDA approved the quadrivalent vaccine for males in 2009, and by 2020, 35 countries had begun vaccinating boys alongside girls.16Cancer Epidemiology, Biomarkers & Prevention. A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination Gender-neutral vaccination programs help reduce HPV’s harmful effects across both sexes and are particularly important for men who have sex with men, who do not benefit from herd immunity generated by female-only vaccination.17PubMed Central. Breaking barriers: why including boys and men is key to HPV prevention The shift from female-only to gender-neutral recommendations took about a decade in most countries, a delay that likely contributed to preventable HPV-related disease in men during that window.
Fewer Doses, Broader Reach
The original HPV vaccination schedule called for three doses over six months. This was a significant logistical hurdle, especially in low-resource settings where getting adolescents back for second and third appointments months later proved difficult. Over time, immunological studies showed that adolescents mounted immune responses to two doses that were as strong as the responses young women had after three, which opened the door to two-dose schedules for younger age groups.
More recently, evidence from long-term follow-up of cohorts and randomized trials has accumulated showing that even a single dose can prevent persistent infection with the most dangerous HPV types, particularly HPV 16 and 18, and sustain immune responses over time in adolescents and young women. Some programmatic recommendations now include one- or two-dose schedules for immunocompetent adolescents, while keeping multi-dose regimens for people with weakened immune systems or in settings where maximizing individual protection is the priority.18Vacunas (English Edition). From three to one human papillomavirus vaccine dose: Robust evidence, clinical uncertainties, and the role of perspective The move toward fewer doses is one of the most consequential developments since the vaccine’s introduction, because it dramatically lowers the barriers to vaccinating populations in countries where three-visit schedules were simply not feasible.
Vaccination After the Recommended Age Window
The standard recommendation targets preteens around age 11 or 12, with catch-up vaccination through age 26. In 2018, the FDA extended Gardasil 9’s approval to adults aged 27 through 45, and the vaccine has shown durable protection in that age group. A study of women aged 27 to 45 found sustained antibody responses and protection against HPV-related disease for roughly ten years after the third dose.19PubMed Central. Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years
However, the cost-effectiveness picture changes sharply with age. Modeling studies in the United States found that extending vaccination to women and men through age 45 produced only small additional health benefits beyond the current recommendations, at substantially higher cost per unit of benefit gained.20PubMed Central. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States A separate analysis estimated the cost per quality-adjusted life-year of vaccinating people through age 45 at several hundred thousand dollars or more, a threshold most health systems consider poor value at the population level.21PLOS Medicine. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis This does not mean the vaccine is worthless for someone in that age range who has not been vaccinated. It means that the population-level return on investment declines because most older adults have already been exposed to HPV, and the vaccine only prevents new infections; it does not treat existing ones. The decision for individuals over 26 is a shared one between patient and provider, weighing personal risk factors and the likelihood of future new exposure.
Safety After 23 Million Doses and Counting
The HPV vaccine’s longevity on the market means its safety record is now one of the most scrutinized of any vaccine. In the first two and a half years after the quadrivalent vaccine was licensed, the U.S. Vaccine Adverse Event Reporting System received about 12,400 reports after more than 23 million distributed doses, a reporting rate of roughly 54 per 100,000 doses. Most reported events were minor and consistent with what any injection causes: pain at the injection site, fainting (common in adolescents receiving any shot), headache, and nausea.22JAMA. Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
Despite this reassuring data, the HPV vaccine became a lightning rod for controversy that had little to do with its safety profile. Some parents expressed concern that vaccinating preteens against a sexually transmitted infection would encourage earlier or riskier sexual behavior. Studies have consistently failed to find any such association, but the cultural discomfort persists in some communities.23PubMed Central. Pros, cons, and ethics of HPV vaccine in teens—Why such controversy? Ironically, the controversy over a vaccine with one of the strongest evidence bases in modern medicine probably contributed to slower uptake in some populations, delaying the very cancer prevention the vaccine was designed to deliver.
The Global Access Problem
One of the starkest realities of the HPV vaccine’s nearly two-decade history is the gap between what it can do and where it has reached. In high-income countries with school-based programs, coverage has climbed high enough to produce visible population-level declines in disease. In low- and middle-income countries, where cervical cancer burden is greatest, the picture is far less encouraging.
Cost is a central barrier. The HPV vaccine has been described as the most expensive childhood immunization in the world, with list prices reaching hundreds of dollars for a full course.24PubMed Central. A guide to global access to HPV vaccination to all women in low- and middle-income countries; a minireview of innovation and equity Organizations like Gavi, the Vaccine Alliance, have negotiated reduced prices for eligible countries, and the shift toward single-dose schedules could dramatically lower per-person costs. Still, reaching girls in remote areas, building cold chains for vaccine storage, and training health workers all require sustained investment. A meta-regression across 195 countries found that the cost per unit of health benefit varies enormously by setting: in countries with the highest cervical cancer rates, the cost-effectiveness is excellent, while in countries where cervical cancer is already rare, the returns are much smaller.25PubMed Central. Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis The places that need the vaccine most are, painfully, the places least able to afford and deliver it.
The WHO Elimination Goal
In 2020, the World Health Organization adopted a global strategy to eliminate cervical cancer as a public health problem, defined as reducing incidence below four cases per 100,000 women. The strategy sets 2030 targets: 90 percent of girls fully vaccinated by age 15, 70 percent of women screened with a high-performance test by ages 35 and 45, and 90 percent of women with cervical disease receiving appropriate treatment.26PubMed Central. Strategic approaches for global cervical cancer elimination: An update review and call for national action Modeling studies have estimated the potential impact of meeting these targets over the coming century, particularly in the low-income and lower-middle-income countries where most cervical cancer deaths occur.27The Lancet. Impact of scaled-up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in LMICs: a modelling study
Whether these targets will be met is a genuinely open question. The COVID-19 pandemic disrupted routine immunization programs worldwide, and in many countries HPV vaccination coverage has not recovered. The gap between the WHO’s ambitious timeline and the ground-level realities of health infrastructure in sub-Saharan Africa and South Asia remains wide.
Therapeutic Vaccines on the Horizon
Every HPV vaccine currently on the market is prophylactic: it prevents infection but cannot treat one that has already taken hold. For the millions of people worldwide already living with HPV infections or HPV-related precancerous lesions, a prophylactic vaccine offers no direct help. This is why a parallel line of research has pursued therapeutic HPV vaccines, designed to train the immune system to attack cells already harboring the virus.
Early therapeutic vaccine candidates struggled. Limited efficacy, delivery challenges, and study design problems prevented several from advancing past initial testing. But DNA-based candidates have recently shown more promise and are moving through mid- to late-stage clinical trials. These vaccines work by stimulating the body’s own T-cells to target HPV proteins expressed in infected cells. While none have yet been approved for commercial use, they can induce regression of precancerous lesions in some patients.28PubMed Central. Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials In one small trial, a DNA vaccine called GX-188E produced complete regression of high-grade cervical lesions and viral clearance in seven out of nine patients within 36 weeks, with no serious adverse events.29Nature Communications. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
A therapeutic vaccine that could clear existing HPV infections would be transformative, particularly in countries where decades of under-screening have left large populations with undetected precancerous disease. Combined with the prophylactic vaccines already in use, it could close the gap between prevention and treatment that currently leaves many people behind. The science is still early, and the jump from nine patients to millions is enormous. But the fact that these candidates exist at all represents a meaningful expansion of what the HPV vaccine story might look like in its next two decades.